
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
aggrecan CRISPR/Cas9 KO Plasmid (h) | sc-400760 | 20 µg | $397.00 |
ACAN encodes aggrecan, a large chondroitin sulfate proteoglycan that forms the hydrated backbone of cartilage extracellular matrix by binding hyaluronan and link protein, enabling resistance to compressive load. Aggrecan turnover is coordinated by chondrocyte anabolic programs and catabolic extracellular proteolysis, including cleavage by ADAMTS aggrecanases and matrix remodeling pathways that shape tissue biomechanics. Perturbation of ACAN expression or aggrecan processing disrupts cartilage homeostasis and is implicated in degenerative and developmental skeletal phenotypes, making it a key node for studying extracellular matrix organization and mechanobiology. ACAN is therefore widely used as a marker and functional determinant in chondrocyte differentiation, growth plate biology, and cartilage matrix assembly studies.
aggrecan CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ACAN gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ACAN together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ACAN open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish aggrecan protein expression.
This CRISPR knockout system enables efficient generation of ACAN-deficient cell models for investigation of aggrecan signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.